Skip to main content

Funded Grants

Filter by:
Clear Filters
Filter by:
Michael Levin × Clear Filters

1 results found

Preclinical assessment of a small molecule to treat neurodegeneration and inhibit disability in multiple sclerosis

Canada has one of the highest rates of MS in the world, with treatment costing an estimated $2 billion per year by 2031. Even with modern treatments, persons living with MS accumulate long-term neurological disability over time.

Project ongoing See Project & Researchers
Grant type
Team grants
Area of Research
Neurodegeneration
Competition
2025-2026 Solutions Program Innovation + Impact Grants
Province
Saskatchewan